Saad Khaled, Aboelgheet Amir, Hashim Khalid, Gad Eman F, Elgenidy Anas, Odat Ramez M, Sherif Aya, Altaweel Ahmed, Zahran Asmaa B, Kamal Sara K, Elshimy Abdelrahman, Samir Ahmed, Khaled Anas, Ibrahim Ahmed, Elhoufey Amira, Dailah Hamad Ghaleb, Alruwaili Thamer, Ibrahim Hoda Atef Abdelsattar
Department of Pediatrics, Faculty of Medicine, Assiut University, Egypt.
Department of Pediatrics, Faculty of Medicine, Shaqra University, Dawadmi, Saudi Arabia.
Clin Med Insights Pediatr. 2025 Jun 5;19:11795565251332173. doi: 10.1177/11795565251332173. eCollection 2025.
Current guidelines recommend extensively hydrolyzed cow's milk protein formulas (EHF) as the first-line treatment for infants diagnosed with cow's milk allergy (CMA). Recently, rice hydrolysate formula (RHF) has emerged as a plant-based alternative with potential advantages in taste, cost-effectiveness, and safety.
Our comprehensive systematic review aimed to evaluate the efficacy of RHF in managing CMA and assess the growth standards of children in short-term follow-up.
We searched PubMed, Scopus, Cochrane, Embase, and Web of Science databases for relevant studies published until May 2024. Eligible studies were selected based on the inclusion criteria. Data extraction covered study characteristics, -scores (weight and length for age, weight for length, body mass index [BMI], and head circumference), tolerance, atopic manifestations, IgE levels, and symptoms-based score (SBS). Quality assessment was performed using appropriate tools for different study designs. Data analysis focused on identifying trends in growth parameters and tolerance outcomes among infants with CMA.
Seventeen studies, 1695 infants with CMA, and 145 healthy infants were included in the review. Weight-for-age -scores varied initially but showed improvement after the first month, except in 1 study. It showed a score decreased by an average of 0.69 from the baseline. Length-for-age -scores exhibited inconsistency, and RHF tended to have negative effects but performed better than the soy formula. Weight-for-length -scores indicated RHF as a reasonable alternative in the first 6 months. RHF gradually enhanced BMI over 6 months. Head circumference -scores varied, with RHF showing mixed results compared to cow's milk protein formula. Tolerance to RHF increased steadily over 2 years. Atopic manifestations at 36 months were moderate for RHF. IgE tests revealed similar sensitization rates across different formulas, and RHF showed effectiveness in symptom reduction over 6 months.
This comprehensive review suggests that RHF can effectively substitute cow's milk formula in managing CMA. These formulas are well tolerated in infants, have varying impacts on growth development, and show promise in reducing atopic symptoms.
当前指南推荐深度水解牛奶蛋白配方奶粉(EHF)作为诊断为牛奶过敏(CMA)婴儿的一线治疗方法。最近,大米水解配方奶粉(RHF)作为一种植物性替代品出现,在口感、成本效益和安全性方面具有潜在优势。
我们全面的系统评价旨在评估RHF在管理CMA方面的疗效,并评估短期随访中儿童的生长标准。
我们检索了PubMed、Scopus、Cochrane、Embase和Web of Science数据库,以查找截至2024年5月发表的相关研究。根据纳入标准选择符合条件的研究。数据提取涵盖研究特征、评分(年龄别体重和身长、身长别体重、体重指数[BMI]和头围)、耐受性、特应性表现、IgE水平和基于症状的评分(SBS)。使用适合不同研究设计的工具进行质量评估。数据分析侧重于确定CMA婴儿生长参数和耐受性结果的趋势。
该评价纳入了17项研究、1695名CMA婴儿和145名健康婴儿。年龄别体重评分最初有所不同,但在第一个月后有所改善,1项研究除外。其评分从基线平均下降了0.69。年龄别身长评分不一致,RHF往往有负面影响,但比大豆配方奶粉表现更好。身长别体重评分表明RHF在前6个月是一种合理的替代品。RHF在6个月内逐渐提高BMI。头围评分各不相同,与牛奶蛋白配方奶粉相比,RHF的结果喜忧参半。对RHF的耐受性在2年内稳步提高。36个月时RHF的特应性表现为中度。IgE测试显示不同配方奶粉的致敏率相似,RHF在6个月内显示出减轻症状的效果。
这项全面评价表明,RHF可以有效替代牛奶配方奶粉来管理CMA。这些配方奶粉在婴儿中耐受性良好,对生长发育有不同影响,并在减轻特应性症状方面显示出前景。